Show simple item record

dc.contributor.authorPentheroudakis, Georgeen
dc.contributor.authorMalamou-Mitsi, Vassiliki D.en
dc.contributor.authorBriassoulis, E. Chen
dc.contributor.authorDamala, K.en
dc.contributor.authorVassou, A.en
dc.contributor.authorVartholomatos, G.en
dc.contributor.authorKolaitis, N.en
dc.contributor.authorPavlidis, Nicholasen
dc.creatorPentheroudakis, Georgeen
dc.creatorMalamou-Mitsi, Vassiliki D.en
dc.creatorBriassoulis, E. Chen
dc.creatorDamala, K.en
dc.creatorVassou, A.en
dc.creatorVartholomatos, G.en
dc.creatorKolaitis, N.en
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:54:28Z
dc.date.available2018-06-22T09:54:28Z
dc.date.issued2004
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42370
dc.description.abstractBACKGROUND. Patients with resected breast carcinoma who received granulocyte-colony-stimulating factor (G-CSF)-supported adjuvant chemotherapy exhibited an increase in their serum CA 15-3 levels. The authors investigated the role of G-CSF-induced neutrophil MUC1 expression in this setting. METHODS. Twenty-two patients with resected early breast carcinoma and 6 patients with high-grade lymphoma received chemotherapy cycles with or without G-CSF support. When given, G-CSF was administered for either 5 or 10 days per cycle. Immunocytochemical staining and flow cytometric analysis of peripheral blood neutrophils and bone marrow myeloid cells for MUC1 epitopes were performed during treatment. RESULTS. At baseline, the median serum CA 15-3 was 16 U/mL, with weak MUC1 expression in peripheral neutrophils (median immunocytochemical score [ICCS] = 40, flow cytometric score [FCS] = 211 antibody molecules per neutrophil). For patients receiving chemotherapy cycles with 5-day G-CSF support, median CA 15-3 levels increased moderately (median = 28 U/mL; P = 0.016) and absolute neutrophil counts (ANC) did not increase, whereas ICC staining showed a moderate increase (median ICCS = 105; P = 0.015). For patients receiving chemotherapy cycles with 10-day G-CSF, serum CA 15-3 levels increased 2-4-fold from baseline levels and reached abnormal levels (median = 47; P < 0.0005) and the ANC increased (median = 21,400/mm3; P = 0.007), whereas significant induction of MUC1 expression occurred in the cell membrane and mostly in the cytoplasm of neutrophils (median ICCS = 162; P = 0.001). Flow cytometry detected increased cytoplasmic, but not surface, neutrophil MUC1 expression in the 10-day G-CSF group only (baseline median FCS = 3975, 4th cycle median = 6327 molecules per cell; P = 0.028). In the bone marrow, induction of MUC1 expression was observed in the 10-day G-CSF group only in band forms and neutrophils, but not in more immature myeloid cells. Serum CA 15-3 levels and ICC score were found to demonstrate a linear relation. When ICCS and ANC were incorporated in a combined score, its relation with serum CA 15-3 levels demonstrated a parabolic (cubic) pattern. Serum CA 15-3 levels, ANC, and neutrophil MUC1 staining returned to baseline after the completion of therapy. No excess of malignant recurrences were observed. CONCLUSIONS. Women with resected breast carcinoma who received G-CSF-primed chemotherapy showed serum CA 15-3 elevation due to an increase in peripheral blood neutrophil number and induced neutrophil cytoplasmic MUC1 expression, which was caused by G-CSF. Physicians should be aware of this interaction. © 2004 American Cancer Society.en
dc.language.isoengen
dc.sourceCanceren
dc.subjectArticleen
dc.subjectBleomycinen
dc.subjectCyclophosphamideen
dc.subjectDacarbazineen
dc.subjectDoxorubicinen
dc.subjectEtoposideen
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectMethotrexateen
dc.subjectPrednisoneen
dc.subjectProcarbazineen
dc.subjectVincristineen
dc.subjectAdenocarcinomaen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast neoplasmsen
dc.subjectFemaleen
dc.subjectMiddle ageden
dc.subjectChemotherapyen
dc.subjectPaclitaxelen
dc.subjectPriority journalen
dc.subjectBone marrowen
dc.subjectClinical articleen
dc.subjectGranulocyte colony-stimulating factoren
dc.subjectProspective studiesen
dc.subjectGranulocyte colony stimulating factoren
dc.subjectEpirubicinen
dc.subjectCarcinomaen
dc.subjectMaleen
dc.subjectAdjuvanten
dc.subjectBreast carcinomaen
dc.subjectProtein expressionen
dc.subjectNeoplasm invasivenessen
dc.subjectMastectomyen
dc.subjectCancer adjuvant therapyen
dc.subjectBiologicalen
dc.subjectCa-15-3 antigenen
dc.subjectMuc1en
dc.subjectTumor markersen
dc.subjectImmunocytochemistryen
dc.subjectCa 15-3en
dc.subjectFlow cytometryen
dc.subjectNeutrophilen
dc.subjectLymphomaen
dc.subjectBone marrow cellen
dc.subjectCa 15-3 antigenen
dc.subjectCell membraneen
dc.subjectCytoplasmen
dc.subjectDuctalen
dc.subjectGranulocyte-colony-stimulating factor (g-csf)en
dc.subjectMucin 1en
dc.subjectNeutrophiliaen
dc.subjectNeutrophilsen
dc.titleThe neutrophil, not the tumor: Serum CA 15-3 elevation as a result of granulocyte-colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapyen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/cncr.20581
dc.description.volume101
dc.description.issue8
dc.description.startingpage1767
dc.description.endingpage1775
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidPentheroudakis, George [0000-0002-6632-2462]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-6632-2462


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record